2007
DOI: 10.1002/jps.20992
|View full text |Cite
|
Sign up to set email alerts
|

Effects of Cyclodextrins on Drug Delivery Through Biological Membranes

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

3
158
0
2

Year Published

2011
2011
2017
2017

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 274 publications
(171 citation statements)
references
References 92 publications
3
158
0
2
Order By: Relevance
“…In previous studies dimethyl-b-Cd and methyl-b-Cd modified cyclodextrins were shown to markedly reduce the viability of Caco-2 cells at concentrations greater than 50 mM. In our study, we found that Hp-b-Cd inclusion complexes were more cytotoxic against Caco-2 cells, consistent with previous results (Loftsson et al, 2007).…”
Section: Discussionsupporting
confidence: 92%
See 2 more Smart Citations
“…In previous studies dimethyl-b-Cd and methyl-b-Cd modified cyclodextrins were shown to markedly reduce the viability of Caco-2 cells at concentrations greater than 50 mM. In our study, we found that Hp-b-Cd inclusion complexes were more cytotoxic against Caco-2 cells, consistent with previous results (Loftsson et al, 2007).…”
Section: Discussionsupporting
confidence: 92%
“…The external component of Cd, which contains many hydrophilic hydroxide groups, may improve the interaction between Cd and cells (Yunomae et al, 2003;Loftsson et al, 2007). Yang et al (2007) reported that the introduction of a-Cd decreased the cytotoxicity of polyether-imide (PEI).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Various derivatives of cyclo- unstirred water layer on their surface which can be 100 mm thick 39 (Lennernas, 1998;Loftsson et al, 2007). Hydrophilic cyclodextrins 40 can increase the drug transport only if the resistance of UWL on 41 donor side is equal or higher than the resistance of membrane barrier Masson et al, 1999).…”
Section: Introductionmentioning
confidence: 99%
“…This is achieved by making the drug available at the surface of the biological barrier, e.g., skin, mucosa, or the eye cornea, from where it partitions into the membrane without disrupting the lipid layers of the barrier [9]. In such cases, it is important to use just enough cyclodextrin to solubilise the drug in the aqueous vehicle since excess cyclodextrin may decrease the drug bioavailability [10]. In the case of water-soluble drugs e.g.…”
Section: Introductionmentioning
confidence: 99%